Diagnostic applications of nuclear medicine: Lung and mediastinal tumors

Elite Arnon-Sheleg; Thida Win; Ora Israel; Ludmila Guralnik; Mor Moskovitz; Simona Ben-Haim

doi:10.1007/978-3-031-05494-5_13

Diagnostic applications of nuclear medicine: Lung and mediastinal tumors

Elite Arnon-Sheleg, Thida Win, Ora Israel, Ludmila Guralnik, Mor Moskovitz, Simona Ben-Haim

Bar-Ilan University - Azrieli Faculty of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

While CT and MRI provide high-resolution anatomic assessment of lung and mediastinal malignancies, [¹⁸F]FDG imaging is superior in differentiating benign from malignant lymphadenopathy and in the detection of distant metastases. Pre-therapy assessment with [¹⁸F]FDG PET/CT can provide important prognostic information. In addition, [¹⁸F]FDG PET/CT can eliminate about half of futile thoracotomies and is therefore recommended for staging of lung and mediastinal tumors. [¹⁸F]FDG imaging is also indicated in the diagnosis of recurrent disease and in monitoring treatment. [¹⁸F]FDG PET/CT has been introduced for radiation planning, enabling refining treatment volumes to allow increased dose in target volume and reduced toxicity to nontarget tissues. Although [¹⁸F]FDG is the most widely used tracer in oncology, other PET tracers are evaluated with specific clinical and research goals and may have a future role in the management of lung malignancies.

Original language	English
Title of host publication	Nuclear Oncology
Subtitle of host publication	From Pathophysiology to Clinical Applications
Publisher	Springer International Publishing
Pages	743-809
Number of pages	67
ISBN (Electronic)	9783031054945
ISBN (Print)	9783031054938
DOIs	https://doi.org/10.1007/978-3-031-05494-5_13
State	Published - 4 Oct 2022

Bibliographical note

Publisher Copyright:
© Springer Nature Switzerland AG 2022.

Keywords

Lung and mediastinal tumor imaging
Lung cancer
Staging of lung and mediastinal tumors
[F]FDG imaging in lung cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-3-031-05494-5_13

Cite this

@inbook{a48bb678723d4c17941b5d1ee8bd6320,

title = "Diagnostic applications of nuclear medicine: Lung and mediastinal tumors",

abstract = "While CT and MRI provide high-resolution anatomic assessment of lung and mediastinal malignancies, [18F]FDG imaging is superior in differentiating benign from malignant lymphadenopathy and in the detection of distant metastases. Pre-therapy assessment with [18F]FDG PET/CT can provide important prognostic information. In addition, [18F]FDG PET/CT can eliminate about half of futile thoracotomies and is therefore recommended for staging of lung and mediastinal tumors. [18F]FDG imaging is also indicated in the diagnosis of recurrent disease and in monitoring treatment. [18F]FDG PET/CT has been introduced for radiation planning, enabling refining treatment volumes to allow increased dose in target volume and reduced toxicity to nontarget tissues. Although [18F]FDG is the most widely used tracer in oncology, other PET tracers are evaluated with specific clinical and research goals and may have a future role in the management of lung malignancies.",

keywords = "Lung and mediastinal tumor imaging, Lung cancer, Staging of lung and mediastinal tumors, [F]FDG imaging in lung cancer",

author = "Elite Arnon-Sheleg and Thida Win and Ora Israel and Ludmila Guralnik and Mor Moskovitz and Simona Ben-Haim",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2022.",

year = "2022",

month = oct,

day = "4",

doi = "10.1007/978-3-031-05494-5_13",

language = "אנגלית",

isbn = "9783031054938",

pages = "743--809",

booktitle = "Nuclear Oncology",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Diagnostic applications of nuclear medicine

T2 - Lung and mediastinal tumors

AU - Arnon-Sheleg, Elite

AU - Win, Thida

AU - Israel, Ora

AU - Guralnik, Ludmila

AU - Moskovitz, Mor

AU - Ben-Haim, Simona

PY - 2022/10/4

Y1 - 2022/10/4

N2 - While CT and MRI provide high-resolution anatomic assessment of lung and mediastinal malignancies, [18F]FDG imaging is superior in differentiating benign from malignant lymphadenopathy and in the detection of distant metastases. Pre-therapy assessment with [18F]FDG PET/CT can provide important prognostic information. In addition, [18F]FDG PET/CT can eliminate about half of futile thoracotomies and is therefore recommended for staging of lung and mediastinal tumors. [18F]FDG imaging is also indicated in the diagnosis of recurrent disease and in monitoring treatment. [18F]FDG PET/CT has been introduced for radiation planning, enabling refining treatment volumes to allow increased dose in target volume and reduced toxicity to nontarget tissues. Although [18F]FDG is the most widely used tracer in oncology, other PET tracers are evaluated with specific clinical and research goals and may have a future role in the management of lung malignancies.

AB - While CT and MRI provide high-resolution anatomic assessment of lung and mediastinal malignancies, [18F]FDG imaging is superior in differentiating benign from malignant lymphadenopathy and in the detection of distant metastases. Pre-therapy assessment with [18F]FDG PET/CT can provide important prognostic information. In addition, [18F]FDG PET/CT can eliminate about half of futile thoracotomies and is therefore recommended for staging of lung and mediastinal tumors. [18F]FDG imaging is also indicated in the diagnosis of recurrent disease and in monitoring treatment. [18F]FDG PET/CT has been introduced for radiation planning, enabling refining treatment volumes to allow increased dose in target volume and reduced toxicity to nontarget tissues. Although [18F]FDG is the most widely used tracer in oncology, other PET tracers are evaluated with specific clinical and research goals and may have a future role in the management of lung malignancies.

KW - Lung and mediastinal tumor imaging

KW - Lung cancer

KW - Staging of lung and mediastinal tumors

KW - [F]FDG imaging in lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85153810314&partnerID=8YFLogxK

U2 - 10.1007/978-3-031-05494-5_13

DO - 10.1007/978-3-031-05494-5_13

M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.chapter???

AN - SCOPUS:85153810314

SN - 9783031054938

SP - 743

EP - 809

BT - Nuclear Oncology

PB - Springer International Publishing

ER -

Diagnostic applications of nuclear medicine: Lung and mediastinal tumors

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this